What is MaxCyte?
MaxCyte operates at the intersection of life sciences and therapeutic innovation, specializing in the development of a versatile cell engineering platform. By leveraging its proprietary technology, the company enables the rapid, scalable, and efficient modification of cells, which is essential for the next generation of cell-based therapies. This platform serves as a critical enabler for both internal pipeline development and external partnerships, positioning MaxCyte as a foundational infrastructure provider in the rapidly evolving landscape of regenerative medicine and oncology.
How much funding has MaxCyte raised?
MaxCyte has raised a total of $77.3M across 6 funding rounds:
Series A
$8M
Series B
$10.7M
Stock Offering
$14.4M
Share Placement
$12.3M
Debt
$1M
Share Placement
$30.9M
Series A (2003): $8M with participation from Undisclosed
Series B (2004): $10.7M led by Tall Oaks Capital, Harbert Venture Partners, and Intersouth Partners
Stock Issuance/Offering (2016): $14.4M supported by Undisclosed
Share Placement (2019): $12.4M featuring Undisclosed
Debt (2020): $1M backed by PPP
Share Placement (2020): $30.9M with participation from Sofinnova Crossover and Casdin Capital
Key Investors in MaxCyte
Tall Oaks Capital
A venture firm focused on the Mid-Atlantic and Southeastern U.S. that prioritizes management strength, market innovation, and defensible proprietary technology in its early-stage investments.
Harbert Venture Partners
A private equity firm with a broad mandate across the U.S. and Europe, specializing in life sciences, technology, and middle-market growth opportunities.
Casdin Capital
An investment firm dedicated to the life sciences sector, providing long-term capital and deep industry expertise to pioneers in diagnostics and molecular information.
What's next for MaxCyte?
With the recent influx of capital, MaxCyte is well-positioned to transition its clinical programs into more advanced phases of development. The strategic focus will likely center on expanding the utility of its cell engineering platform across diverse therapeutic modalities, including CAR-T and other gene-edited therapies. As the company scales, it will continue to leverage its robust intellectual property estate to maintain a competitive edge, while simultaneously deepening its collaborative efforts with global biopharmaceutical partners to bring life-saving treatments to patients worldwide.
See full MaxCyte company page
